Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ritter Pharmac. Com (RTTR)

Ritter Pharmac. Com (RTTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,677
  • Shares Outstanding, K 46,153
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,130 K
  • 60-Month Beta -0.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.33
Trade RTTR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.64
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 05/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2850 +57.19%
on 04/23/20
0.7900 -43.29%
on 05/18/20
+0.1540 (+52.38%)
since 04/22/20
3-Month
0.1700 +163.53%
on 03/16/20
0.8600 -47.91%
on 03/02/20
+0.2151 (+92.36%)
since 02/21/20
52-Week
0.1500 +198.67%
on 12/26/19
1.2700 -64.72%
on 07/02/19
-0.3820 (-46.02%)
since 05/22/19

Most Recent Stories

More News
Docbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEO

Docbot, Inc. , an artificial intelligence (AI) technology company focusing on gastrointestinal (GI) disease, announced today the closing of a Series A round. In conjunction with the financing, the company...

RTTR : 11.2000 (+1.82%)
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.

LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction...

RTTR : 11.2000 (+1.82%)
Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.

LOS ANGELES, May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final...

RTTR : 11.2000 (+1.82%)
Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting

LOS ANGELES, May 14, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter” or the “Company”), today announced that it has adjourned its special meeting of stockholders,...

RTTR : 11.2000 (+1.82%)
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing

LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from...

RTTR : 11.2000 (+1.82%)
Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals

LOS ANGELES, May 06, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that Institutional Shareholder Services...

RTTR : 11.2000 (+1.82%)
Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020

LOS ANGELES, May 01, 2020 (GLOBE NEWSWIRE) -- Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway

RTTR : 11.2000 (+1.82%)
Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.

The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split.

RTTR : 11.2000 (+1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance....

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 0.5758
1st Resistance Point 0.5119
Last Price 11.2000
1st Support Level 0.4121
2nd Support Level 0.3762
3rd Support Level N/A

See More

Last Price 11.2000
52-Week High 1.2700
Fibonacci 61.8% 0.8422
Fibonacci 50% 0.7100
Fibonacci 38.2% 0.5778
52-Week Low 0.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar